title: MiR-200c and HuR in ovarian cancer.
abstract: BACKGROUND
  MicroRNAs in solid malignancies can behave as predictors of either good or poor outcome. This is the case with members of the miR-200 family, which are the primary regulators of the epithelial to mesenchymal transition and have been reported to act as both oncogenes and tumor suppressors. This study assessed the role of miR-200c as regulator of class III β-tubulin (TUBB3), a factor associated with drug-resistance and poor prognosis in ovarian cancer.
  
  
  METHODS
  Expression of miR-200c was assessed in a panel of ovarian cancer cell lines with inherent or acquired drug-resistance. Stable overexpression of miR-200c was obtained in A2780 and Hey cell lines. Crosslinking-coupled affinity purification method and ribonucleic-immunoprecipitation assay were used to characterise the complexes between miR-200c, HuR and 3'UTR region of TUBB3 mRNA. Nanofluidic technology and immunohistochemistry were used to analyze the expression of HuR, TUBB3 and miR-200c in 220 ovarian cancer patients.
  
  
  RESULTS
  In a panel of ovarian adenocarcinoma cell lines, we observed a direct correlation between miR-200c expression and chemoresistance. In A2780 cells miR-200c targeted TUBB3 3'UTR, while a positive correlation was observed between miR-200c and TUBB3 expression in most of the other cell lines. Through the analysis of 3'UTR-associated complexes, we found that the miR-200c can increase the association of the RNA binding protein HuR with TUBB3 mRNA, whereas HuR binding enhanced TUBB3 mRNA translation. Most importantly, in our analysis on 220 ovarian cancer patients we observed that overexpression of miR-200c correlated with poor or good outcome depending on the cellular localization of HuR.
  
  
  CONCLUSIONS
  This study suggests a model for the combined regulatory activity of miR-200c and HuR on TUBB3 expression in ovarian cancer. When HuR is nuclear, high expression of miR-200c inhibits TUBB3 expression and results in a good prognosis, whereas when HuR occurs in cytoplasm, the same miRNA enhances TUBB3 expression and produces a poor outcome. These findings reveal the usefulness of multidimensional analysis in the investigation of the prognostic role of miRNA expression.
authors: Laboratory of Antineoplastic Pharmacology, Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome 00168, Italy.
authors: Silvia
authors: S
authors: Prislei
authors: Enrica
authors: E
authors: Martinelli
authors: Marisa
authors: M
authors: Mariani
authors: Giuseppina
authors: G
authors: Raspaglio
authors: Steven
authors: S
authors: Sieber
authors: Gabriella
authors: G
authors: Ferrandina
authors: Shohreh
authors: S
authors: Shahabi
authors: Giovanni
authors: G
authors: Scambia
authors: Cristiano
authors: C
authors: Ferlini
mesh_terms: D020413:3' Untranslated Regions; D000230:Adenocarcinoma / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000970:Antineoplastic Agents / Q000494:pharmacology; D001665:Binding Sites; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D003593:Cytoplasm / Q000378:metabolism; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D051959:ELAV Proteins / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005947:Glucose / Q000172:deficiency; D006801:Humans; D007150:Immunohistochemistry; D047468:Immunoprecipitation; D053208:Kaplan-Meier Estimate; D035683:MicroRNAs / Q000378:metabolism*; D046210:Microfluidic Analytical Techniques; D008875:Middle Aged; D015999:Multivariate Analysis; D036103:Nanotechnology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017239:Paclitaxel / Q000494:pharmacology; D016016:Proportional Hazards Models; D034622:RNA Interference; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D014404:Tubulin / Q000235:genetics / Q000378:metabolism
chemical_list: D020413:3' Untranslated Regions; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D051959:ELAV Proteins; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; C498585:TUBB3 protein, human; D014404:Tubulin; D005947:Glucose; D017239:Paclitaxel; D002945:Cisplatin
references: Mol Cell. 2011 Aug 5;43(3):327-39
references: 21723170
references: Cell. 2007 Mar 23;128(6):1105-18
references: 17382880
references: Gynecol Oncol. 2009 Sep;114(3):457-64
references: 19501389
references: Cancer Res. 2010 Jul 15;70(14):5891-900
references: 20587520
references: Nat Rev Genet. 2010 Sep;11(9):597-610
references: 20661255
references: J Cell Physiol. 2012 Mar;227(3):1034-41
references: 21520077
references: J Cell Biochem. 2009 Aug 15;107(6):1053-62
references: 19479945
references: Int J Biochem Cell Biol. 2010 Jan;42(1):25-30
references: 19854294
references: Clin Cancer Res. 2006 May 1;12(9):2774-9
references: 16675570
references: Gynecol Oncol. 2009 Aug;114(2):253-9
references: 19446316
references: Mol Cancer Ther. 2009 May;8(5):1055-66
references: 19435871
references: Wiley Interdiscip Rev RNA. 2010 Sep-Oct;1(2):214-29
references: 21935886
references: J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63
references: 17105988
references: Clin Cancer Res. 2008 May 1;14(9):2690-5
references: 18451233
references: Gene. 2008 Feb 15;409(1-2):100-8
references: 18178340
references: Lancet Oncol. 2011 Mar;12(3):273-85
references: 21345725
references: Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90
references: 20083225
references: Cancer Res. 2007 Sep 15;67(18):8699-707
references: 17875710
references: Adv Exp Med Biol. 2013;768:97-126
references: 23224967
references: Cancer Res. 2005 Mar 15;65(6):2397-405
references: 15781655
references: Mol Cancer Ther. 2012 Dec;11(12):2556-65
references: 23074172
references: Endocr Relat Cancer. 2010 Dec 21;18(1):85-95
references: 21051560
references: J Oncol. 2010;2010:821717
references: 20049172
references: Cancer Res. 2007 Oct 1;67(19):9356-63
references: 17909044
references: Nat Rev Genet. 2009 Oct;10(10):704-14
references: 19763153
references: EMBO Rep. 2010 Sep;11(9):670-7
references: 20706219
references: Nat Rev Cancer. 2011 Aug 05;11(9):644-56
references: 21822212
references: Cancer Res. 2008 Dec 15;68(24):10197-204
references: 19074887